Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthtech Industry Analysis

UpdatedAug 04, 2026
DataAggregated Company Financials
Companies68
  • 7D0.5%
  • 3M14.4%
  • 1Y-32.7%
  • YTD-13.9%

The Healthtech industry has been flat over the last week, but Teladoc Health has lost 29%. As for the longer term, the industry has declined 33% in the last year. Looking forward, earnings are forecast to grow by 20% annually.

Industry Valuation and Performance

Has the U.S. Healthtech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 04 Aug 2026US$53.3bUS$13.4b-US$387,972,179.0033.9x-137.4x4x
Thu, 02 Jul 2026US$49.1bUS$13.8b-US$457,040,179.0032.2x-107.5x3.6x
Sat, 30 May 2026US$46.5bUS$14.2b-US$790,217,326.0030.8x-58.8x3.3x
Mon, 27 Apr 2026US$46.5bUS$13.6b-US$417,856,415.0031.1x-111.2x3.4x
Wed, 25 Mar 2026US$49.9bUS$13.6b-US$385,844,265.0032.9x-129.4x3.7x
Fri, 20 Feb 2026US$49.5bUS$13.7b-US$97,099,340.0044.1x-509.5x3.6x
Sun, 18 Jan 2026US$63.5bUS$13.6b-US$102,102,340.0051.7x-621.8x4.7x
Tue, 16 Dec 2025US$64.1bUS$13.6b-US$100,808,271.0056x-635.9x4.7x
Thu, 13 Nov 2025US$77.0bUS$13.1b-US$31,855,903.0060.1x-2416.5x5.9x
Sat, 11 Oct 2025US$82.7bUS$13.1b-US$211,110,296.0058x-391.9x6.3x
Mon, 08 Sep 2025US$77.2bUS$13.2b-US$266,647,296.0055.2x-289.5x5.8x
Wed, 06 Aug 2025US$76.5bUS$13.3b-US$584,954,447.0058.7x-130.8x5.8x
Fri, 04 Jul 2025US$79.4bUS$13.2b-US$1,382,394,447.0055.7x-57.4x6x
Sun, 01 Jun 2025US$75.2bUS$13.2b-US$1,382,409,796.0055.6x-54.4x5.7x
Tue, 29 Apr 2025US$68.5bUS$13.2b-US$1,417,865,959.0052.8x-48.3x5.2x
Thu, 27 Mar 2025US$72.0bUS$13.2b-US$1,405,690,435.0057.3x-51.2x5.5x
Sat, 22 Feb 2025US$73.1bUS$13.0b-US$1,560,607,514.0061.2x-46.9x5.6x
Mon, 20 Jan 2025US$66.3bUS$12.9b-US$1,638,054,514.0055.2x-40.5x5.1x
Wed, 18 Dec 2024US$67.9bUS$12.9b-US$1,636,315,514.0055.9x-41.5x5.3x
Fri, 15 Nov 2024US$68.4bUS$12.8b-US$1,660,182,370.0055.8x-41.2x5.3x
Sun, 13 Oct 2024US$65.0bUS$14.0b-US$3,264,789,368.0053.6x-19.9x4.7x
Tue, 10 Sep 2024US$66.2bUS$14.0b-US$3,301,808,821.0056.8x-20.1x4.7x
Thu, 08 Aug 2024US$57.0bUS$13.7b-US$3,384,722,079.0050.2x-16.8x4.2x
Sat, 06 Jul 2024US$55.9bUS$13.7b-US$1,860,692,542.0049.9x-30.1x4.1x
Mon, 03 Jun 2024US$52.7bUS$12.7b-US$1,885,422,856.0046.6x-28x4.1x
Wed, 01 May 2024US$57.1bUS$12.7b-US$1,630,193,679.0045.4x-35x4.5x
Fri, 29 Mar 2024US$65.3bUS$14.3b-US$1,512,777,253.0050.5x-43.1x4.6x
Sun, 25 Feb 2024US$63.3bUS$14.0b-US$1,904,502,794.0053.4x-33.3x4.5x
Tue, 23 Jan 2024US$74.2bUS$18.3b-US$5,780,316,752.0059.5x-12.8x4.1x
Thu, 21 Dec 2023US$70.3bUS$18.3b-US$5,781,192,665.0054.9x-12.2x3.8x
Sat, 18 Nov 2023US$65.4bUS$18.2b-US$5,940,504,804.0052.5x-11x3.6x
Mon, 16 Oct 2023US$71.2bUS$18.0b-US$5,559,240,965.0053.4x-12.8x3.9x
Wed, 13 Sep 2023US$75.3bUS$18.0b-US$5,515,729,389.0048.9x-13.7x4.2x
Fri, 11 Aug 2023US$73.4bUS$17.9b-US$5,560,084,123.0062.1x-13.2x4.1x
Price to Earnings Ratio

-13.2x


Total Market Cap: US$73.4bTotal Earnings: -US$5,560,084,123.00Total Revenue: US$17.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthtech Industry Price to Earnings3Y Average -135.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 4.6x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Services industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 9.2% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market2.39%
Healthcare-2.37%
Healthtech0.51%
Healthtech0.51%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VEEV Veeva SystemsUS$206.252.5%
+US$820.3m		-26.7%PE35.6x
HTFL HeartFlowUS$26.764.6%
+US$100.9m		n/aPS12.1x
CERT CertaraUS$8.183.4%
+US$42.0m		-17.0%PS3x
DOCS DoximityUS$21.661.0%
+US$39.5m		-62.6%PE19.9x
CTEV ClaritevUS$24.297.1%
+US$27.6m		-38.5%PS0.4x

Latest News

TDOC
US$6.68
Teladoc Health
7D
-28.6%
1Y
-4.0%
HSTM
US$28.33
HealthStream
7D
-1.8%
1Y
10.1%
DRIO
US$7.10
DarioHealth
7D
-5.3%
1Y
-33.0%
WAY
US$22.66
Waystar Holding
7D
-4.3%
1Y
-34.9%
HCTI
US$1.02
Healthcare Triangle
7D
-37.4%
1Y
-99.6%
CTEV
US$24.29
Claritev
7D
7.1%
1Y
-38.5%
AMWL
US$10.76
American Well
7D
-3.0%
1Y
26.9%
Analysis Article • Jul 28

We Think American Well (NYSE:AMWL) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
LFMD
US$3.73
LifeMD
7D
-2.9%
1Y
-68.5%
VEEV
US$206.25
Veeva Systems
7D
2.5%
1Y
-26.7%
Seeking Alpha • Jul 24

Veeva Systems: Steady Execution, Attractive P/E Multiples

Summary Veeva Systems stands out as a compelling buy amid a potential market rotation into lagging software stocks. VEEV benefits from a highly regulated customer base, strong growth and margin profile, and robust sales execution. After a near-20% YTD decline and recent post-earnings volatility, VEEV's valuation is now especially attractive. I reiterate a buy rating, citing a healthy balance sheet with $7.31B cash and no debt, and favorable enterprise value. Read the full article on Seeking Alpha
HTFL
US$26.76
HeartFlow
7D
4.6%
1Y
n/a
GDRX
US$3.16
GoodRx Holdings
7D
1.3%
1Y
-28.0%
DOCS
US$21.66
Doximity
7D
1.0%
1Y
-62.6%
Narrative Update • Jul 21

DOCS: Clinical AI Safety Leadership Will Support Higher Future Earnings Power

The analyst fair value estimate for Doximity has been reset from $55.00 to $36.89 after multiple firms trimmed price targets, citing concerns about slower core growth, heavier AI investment weighing on margins, and rising competitive and execution risks. Analyst Commentary Recent Street research on Doximity reflects a reset in expectations around growth, profitability, and competitive positioning, particularly as the company leans into heavier AI investment and faces questions about the durability of its core advertising business.
CERT
US$8.18
Certara
7D
3.4%
1Y
-17.0%
EVH
US$3.14
Evolent Health
7D
-16.0%
1Y
-66.9%
Seeking Alpha • Jul 17

Evolent Health: The De-Risking Is Working, But Leverage Keeps Me On Hold

Summary Evolent Health (EVH) is rated Hold, with the equity already pricing in a 2027 EBITDA recovery above current guidance. Recent contract repricing stabilized losses, but core profitability remains pressured; a steep second-half 2026 revenue ramp is critical for validation. EVH’s 6.6x net leverage against volatile cash flows creates significant downside risk if medical expense ratios do not improve. Third quarter 2026 results and evidence of margin normalization are essential catalysts for any re-rating above the current $5 price target. Read the full article on Seeking Alpha
CCLD
US$2.65
CareCloud
7D
12.3%
1Y
11.3%
PHR
US$11.30
Phreesia
7D
4.1%
1Y
-58.3%
Narrative Update • Jul 16

PHR: Securities Lawsuit And Weak Growth Visibility Will Pressure Shares

The analyst price target for Phreesia has been revised from $24 to $9, as analysts weigh lower modeled revenue growth, a reduced assumed future P/E multiple, and sector research that highlights competitive pressures, softer digital advertising trends, and limited visibility into a return to durable organic growth. Analyst Commentary on Phreesia Recent research on Phreesia points to a more cautious stance from several bearish analysts, with multiple downgrades and lower price targets reflecting concerns about growth visibility, competition, and the balance between profitability efforts and future expansion.